|MDACC Study No:||2013-0299 (clinicaltrials.gov NCT No: NCT01841723)|
|Title:||A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Ibrutinib for Treatment of Relapsed Hairy Cell Leukemia|
|Principal Investigator:||Farhad Ravandi-Kashani|
|Study Description:||The goal of this clinical research study is to learn if ibrutinib can help to |
control HCL and vHCL. The safety of this drug will also be studied.